Trichomegaly of the eyelashes after treatment with erlotinib in non-small cell lung cancer.
Carser
Judith Elizabeth
JE
Department of Medical Oncology, Northern Ireland Cancer Centre, Belfast, Northern Ireland. judith.carser@bch.n-i.nhs.uk
Summers
Yvonne Jane
YJ
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects*; D001707:Biopsy, Needle; D001999:Bronchoscopy; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D000069347:Erlotinib Hydrochloride; D005140:Eyelashes / Q000254:growth & development*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006983:Hypertrichosis / Q000139:chemically induced*; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008875:Middle Aged; D009367:Neoplasm Staging; D011799:Quinazolines / Q000009:adverse effects* / Q000627:therapeutic use; D018570:Risk Assessment; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
D011799:Quinazolines; D000069347:Erlotinib Hydrochloride